Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05GZD
|
|||
| Former ID |
DCL000625
|
|||
| Drug Name |
Rilapladib
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Arteriosclerosis [ICD-11: BD40; ICD-9: 440] | Phase 1 | [1], [2] | |
| Cardiovascular disease [ICD-11: BA00-BE2Z; ICD-10: I00-I99] | Phase 1 | [2] | ||
| Company |
GSK
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C40H38F5N3O3S
|
|||
| Canonical SMILES |
COCCN1CCC(CC1)N(CC2=CC=C(C=C2)C3=CC=C(C=C3)C(F)(F)F)C(=O)CN4C5=CC=CC=C5C(=O)C=C4SCC6=C(C(=CC=C6)F)F
|
|||
| InChI |
1S/C40H38F5N3O3S/c1-51-22-21-46-19-17-32(18-20-46)47(24-27-9-11-28(12-10-27)29-13-15-31(16-14-29)40(43,44)45)37(50)25-48-35-8-3-2-6-33(35)36(49)23-38(48)52-26-30-5-4-7-34(41)39(30)42/h2-16,23,32H,17-22,24-26H2,1H3
|
|||
| InChIKey |
NNBGCSGCRSCFEA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 412950-08-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phospholipase A2 (PLA2G1B) | Target Info | Modulator | [3] |
| Platelet-activating factor acetylhydrolase (PLA2G7) | Target Info | Inhibitor | [4], [5] | |
| Thymidine kinase 1 (TK1) | Target Info | Inhibitor | [6] | |
| BioCyc | Phospholipases | |||
| KEGG Pathway | Ether lipid metabolism | |||
| Metabolic pathways | ||||
| Biosynthesis of antibiotics | ||||
| Glycerophospholipid metabolism | ||||
| Arachidonic acid metabolism | ||||
| Linoleic acid metabolism | ||||
| alpha-Linolenic acid metabolism | ||||
| Ras signaling pathway | ||||
| Vascular smooth muscle contraction | ||||
| Pancreatic secretion | ||||
| Fat digestion and absorption | ||||
| Pathway Interaction Database | Lissencephaly gene (LIS1) in neuronal migration and development | |||
| Fc-epsilon receptor I signaling in mast cells | ||||
| Reactome | Acyl chain remodelling of PC | |||
| Acyl chain remodelling of PE | ||||
| Acyl chain remodelling of PI | ||||
| WikiPathways | IL1 and megakaryotyces in obesity | |||
| Synthesis, Secretion, and Deacylation of Ghrelin | ||||
| Glycerophospholipid biosynthesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7376). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018454) | |||
| REF 3 | Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging.J Am Coll Cardiol.2014 Jan 7-14;63(1):86-8. | |||
| REF 4 | Phospholipase A2 inhibitors. Curr Opin Lipidol. 2009 Aug;20(4):327-32. | |||
| REF 5 | THERAPEUTICS: Rilapladib | |||
| REF 6 | Trichomonas vaginalis thymidine kinase: purification, characterization and search for inhibitors. Biochem J. 1998 Aug 15;334 ( Pt 1):15-22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.